VBIV VBI Vaccines Inc.

1.41
0  0%
Previous Close 1.41
Open
Price To Book 2.56
Market Cap 251,342,651
Shares 64,078,781
Volume 35,958
Short Ratio
Av. Daily Volume 6,137,582
Stock charts supplied by TradingView

NewsSee all news

  1. VBI Vaccines Regains Compliance with Nasdaq Minimum Bid Price Requirement

    VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or "the Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it received notice

  2. VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints

    Lot-to-lot manufacturing consistency of Sci-B-Vac®, the primary endpoint, was demonstrated Sci-B-Vac® achieved seroprotection rates of 99.3% and 90.4% after three and two doses, respectively, compared with 94.8% and

  3. VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting

    33% reduction in tumor size observed in one patient in Part B – reduction sustained through two consecutive MRI scans 6-month overall survival (OS) now available for Part A demonstrated benefit for vaccine responders

  4. Brii Biosciences Expands Infectious Disease Pipeline

    Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases Company pipeline now includes up to 12 partnered assets, in addition to internal development

  5. VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

    - Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection - Two-part, dose-escalation study expected to enroll up to 65 patients - Initial data expected in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data presented at SNO meeting November 22, 2019.
VBI-1901
Recurrent glioblastoma multiforme (rGBM)
Phase 3 data met co-primary endpoints but missed key secondary endpoint.
Sci-B-Vac - PROTECT
Hepatitis B vaccine
Phase 2 trial to be initiated 1H 2020.
VBI-1501
Congenital Cytomegalovirus (CMV)
Phase 3 data met primary endpoint - January 9, 2020.
Sci-B-Vac - CONSTANT
Hepatitis B vaccine
Phase 2 trial to be initiated 4Q 2019 with data due 2H 2020.
BRII-179 (VBI-2601)
Hepatitis B vaccine

Latest News

  1. VBI Vaccines Regains Compliance with Nasdaq Minimum Bid Price Requirement

    VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or "the Company"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it received notice

  2. VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints

    Lot-to-lot manufacturing consistency of Sci-B-Vac®, the primary endpoint, was demonstrated Sci-B-Vac® achieved seroprotection rates of 99.3% and 90.4% after three and two doses, respectively, compared with 94.8% and

  3. VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting

    33% reduction in tumor size observed in one patient in Part B – reduction sustained through two consecutive MRI scans 6-month overall survival (OS) now available for Part A demonstrated benefit for vaccine responders

  4. Brii Biosciences Expands Infectious Disease Pipeline

    Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases Company pipeline now includes up to 12 partnered assets, in addition to internal development

  5. VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection

    - Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection - Two-part, dose-escalation study expected to enroll up to 65 patients - Initial data expected in

  6. VBI Vaccines to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the Company's abstract titled,

  7. VBI Vaccines Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Final patient visit completed in CONSTANT study of Sci-B-Vac®, on-track for top-line data expected early January 2020 Entered into collaboration with GSK to evaluate the combination of VBI-1901 with GSK's AS01B

  8. VBI Vaccines Announces Late-Breaker Oral Presentation at IDWeek 2019™

    VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company's abstract

  9. VBI Vaccines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its

  10. VBI Vaccines Announces Pricing of $35 Million Public Offering

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the pricing of its

  11. VBI Vaccines Announces Proposed Public Offering of Common Shares

    VBI Vaccines Inc. (NASDAQ:VBIV) (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an

  12. VBI Vaccines to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology